Основные этапы и перспективы создания вакцин против вирусного гепатита С

02.12.2012

Литература

  1. Гайдаренко А.Д. Прогнозирование проявлений эпидемиологического процесса гепатита С на основе компьютерного моделирования: Автореф. дис. ... к.б.н. - М., 2009. - 24 с.
  2. Потапова А.А., Редченко Е.Б., Богуш П.Г. и др. Эффективность использования массового скрининга крови для определения распространенности и динамики распространения антител к ВГС среди различных групп пациентов ЛПУ г. Москвы / Иммунодиагностика вирусного гепатита С в скрининговой лаборатории при массовых исследованиях. - М., 2008. С. 62 - 76.
  3. Шляхтенко Л.И. Системный подход к изучению эпидемического процесса гепатитов В и С // Эпидемиология и Вакцинопрофилактика. 2003. № 11. С. 15 - 19.
  4. Alter M.J. Epidemiology of hepatitis C virus infection // World J. Gastroenterol. 2007. V. 13. P 2436 - 2441.
  5. Alvarez-Lajonchere L., Shoukry N.H., Gra B. et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in Phase I clinical trial // J. Viral. Hepatol. 2009. V. 26. P 156 - 167.
  6. Bartosch B., Bukh J., Meunier J.C. et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes // PNAS USA. 2003. V. 100. P. 14199 - 14204.
  7. Batdelger D., Dandii D., Jirathitikal V. et al. Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C // Vaccine. 2008. V. 26. P. 2733 - 2737.
  8. Baumert T.F., Wellnitz S., Aono S. et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C // Hepatology. 2000. V. 32. P. 610 - 617.
  9. Bukh J., Miller R.H., Purcell R.H. et al. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes // Semin. Liver. 1995. V. 15. P. 41 - 63.
  10. Choo Q-L., Kuo G., Weiner A.L. et al. Isolation of a cDNA clone from blood-borne non-A, non-B viral hepatirtis genome // Science. 1989. V. 244. P. 359 - 362.
  11. Choo Q-L., Richman H., Han J.H. et al. Genetic organization and diversity of the hepatitis C virus // PNAS USA. 1991. V. 88. P. 2451 - 2455.
  12. Choo Q-L., Kuo G., Ralson R. et al. Vaccination of chimpanzees against infection by hepatitis C virus // PNAS USA. 1994. V. 91. P. 1794 - 1798.
  13. Cox A.L., Mosbruger T., Mao Q. et al. Cellular immune selection with hepatitis C virus persistence in humans // J. Exp. Med. 2005. V. 201. P. 1741 - 1752.
  14. Drane D., Marashovsky E., Gibson R. et al. Priming of CD4(+) and CD8(+) T-cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers // Hum. Vaccine. 2009. V. 5. P. 151 - 157.
  15. Duchini A., Folgoni A., Klenerman P. et al. Vaccination strategies for hepatitis C / Proceedings of the 1st BIT’s Annual world congress of microbes-2011. - China, Beijing, 30 July - 1 August 2011. - 126 p.
  16. Elmowalid G.A., Qiao M., Jeong S.H. et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees // PNAS USA. 2007. V. 104. P 8427 - 8432.
  17. Folgoni A., Capone S., Ruggeri L. et al. T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees // Nat. Med. 2006. V. 12. P. 190 - 197.
  18. Forns X., Payette P.J., Ma X. et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV // Hepatology. 2000. V. 32. P. 618 - 625.
  19. Gerlach J.T., Diepolder H.M., Jung M.C. et al. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C // Gastroenterol. 1999. V. 117. P 933 - 941.
  20. Habersetzer F., Honnet G., Bain C. et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C // Gastroenterol. 2011. V. 141. P. 890 - 899.
  21. Haberstroh A., Schnober E.K., Zeisel M.B. et al. Neutralizing host responses in hepatitis C virus infection targets viral entry at postbinding steps and membrane fusion // Gastroenterol. 2008. V. 135. P. 1719 - 1728.
  22. Klade C.S., Wedemeyer H., Berg T. et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41 // Gastroenterol. 2008. V. 134. P. 13285 - 13295.
  23. Kurbanov F., Tanaka Y., Sugauchi F. et al. Hepatitis C virus molecular epidemiology in Uzbekistan // J. Med. Virol. 2003. V. 69. P 367 - 375.
  24. Lechner F., Wong D.K., Dunbar PR. et al. Analysis of successful immune responses in persons infected with hepatitis C virus // J. Exp. Med. 2001. V. 194. Р. 1395 - 1406.
  25. Miller R.H., Purcell R.H. Hepatitis C virus shares amino acids sequences similarity with pestivirus and flavivirus as well as member of two plant virus supergroups // PNAS USA. 1990. V. 87. P. 2057 - 2061.
  26. Nevens F., Roskams T., van Vlierberghe H. et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C // Hepatology. 2003. V. 38. P 1289 - 1296.
  27. Nielsen S.U., Bassendine M.F., Martin C. et al. Characterization of hepatitis C RNA-containing particles from human liver by density and size // J. Gen. Virol. 2008. V. 89. P. 2507 - 2517.
  28. Park S.H., Shin E.C., Capole S. et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus // Gastroenterol. 2012. V. 143. P. 1048 - 1060.
  29. Ploss A., Evan M.J., von Hahn D.M. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry // Nature. 2007. V. 446. P. 801 - 805.
  30. Puig M., Major M.E., Mihalik K. et al. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection // Vaccine. 2004. V. 22. P. 991 - 1000.
  31. Puig M., Mihalik K., Tilton J.C. et al. CD4+ immun escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus // Hepatology. 2006. V. 44. P 736 - 745.
  32. Rollier C., Depla E., Drexhage J.A. et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response // J. Virol. 2004. V. 78. P. 187 - 196.
  33. Rollier C.S., Paranhos-Bassala G., Verschoor E.J. et al. Vaccine-induced early control of hepatitis C virus in chimpanzees fails to impact on PD-I and chronicity // Hepatology. 2007. V. 45. P. 602 - 613.
  34. Ryder S.D. Outcome of hepatitis C infection: bleak or benign? // J. Hepatol. 2007. V. 47. P 4 - 6.
  35. Sallberg M.M., Frelin L., Diepolder H. et al. A first clinical trials of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects inpatients with chronic hepatitis C / Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver. - Copenhagen, Denmark, 2009. - 167 p.
  36. Simmonds P., Bukh J., Combet C. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes // Hepatol. 2005. V. 42. P. 962 - 973.
  37. Smith D.B., Simmonds P. Review: molecular epidemiology of hepatitis C virus // J. Gastroenterol. Hepatol. 1997. V. 12. P. 522 - 527.
  38. Sominskaya I., Dase S., Dislers A. et al. Construction and immunological evaluation of multinalent hepatitis B virus (HBV) core like particles carrying HBV and HCV epitopes // Clin. Vaccine Immunol. 2010. V. 17. P 1027 - 1033.
  39. Stamataki Z., Coates S., Abrignani S. et al. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that crossneutralize heterologous virus strains // J. Infect. Dis. 2011. V. 204. P. 811 - 813.
  40. Tanaka Y., Kurbanov F., Mano S. et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality // Gastroenterol. 2006. V. 130. P. 703 - 714.
  41. Uebelhoer L., Han J.-H., Callendret B. et al. Stable cytotoxic T-cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness // PLoS Pathogens. 2008. V. 4. - ID e1000143.
  42. Urbani S., Amadei B., Fisicaro P. et al. Outcome of acute hepatitis C virus is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses // Hepatology. 2006. V. 44. P. 126 - 139.
  43. Youn J.W., Park S.H., Lavillette D. et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in chimpanzee // Hepatology. 2005. V. 42. P 1429 - 1436.
  44. Youn J.W., Hu Y.W., Tricoche N. et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with recombinant vaccinia virus // Virol. 2008. V. 82. P. 10896 - 10905.
  45. Yu X., Qiao M., Atanasov I. et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles // Virology. 2007. V. 367. P. 126 - 134.
  46. Yutani S., Yamada A., Yoshida K. et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy // Vaccine. 2007. V. 25. P. 7429 - 7435.
  47. Zhang P., Zhong l., Struble E.B. et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad crossgenotype neutralizing activity // PNAS USA. 2009. V. 106. P 7537 - 7541.
  48. Zeisel M.B., Fari-Kremer S., Robinet E. 6t al. Adaptive immunity to hepatitis C virus // Viruses. 2009. V. 1. P 276 - 297.
  49. Zhong J., Gastaminza P., Cheng G. et al. Robust hepatitis C virus infection in vitro // PNAS USA. 2005. V. 102. P 9294 - 9299.